Anavex Life Sciences Corp (AVXL)

[BarrellofHay]

Here are some facts:

Lecanemab primary endpoint was CDR-SB and data here with time course (to 18 months): https://www.nejm.org/doi/full/10.1056/NEJMoa2212948

Anavex-273 data with time course looks better at week 48 than at week 72 for lecanemab

The patients will be evaluated for Anavex-273 out to 96 weeks.

In other words apples to apples data comparison to lecanemab shows a better outcome for 273 using the primary endpoint that the FDA used to accept the drug for approval. I think this is pretty good and new